Category Archives: Drugs&Dealers

GE Healthcare’s innovation village nurtures early stage science

On 27th April Edwina Hart, Welsh Minister for Economy, Transport and Science and Kieran Murphy, President and CEO of GE Healthcare Life Sciences opened the Life Sciences Innovation Village, a…

Legal and General UK Alpha Fund

The objective of the Legal and General UK Alpha Fund is to provide growth. The fund will typically invest between 90% and 100% in company shares from a small number…

AXA Framlington IM UK and the AXA Biotechnology Fund

AXA Investment Managers, one of the world’s largest asset managers, offers customised investment solutions across all major asset classes and regions. The AXA Framlington Biotech fund provides long-term capital appreciation by investing principally in equity securities…

Banking on biotech with RBC Capital Markets

RBC’s Corporate Banking Group provides leading financial services capabilities for global corporate and institutional clients. Alongside our Global Investment Banking colleagues, we leverage the global capabilities of RBC’s platform and work closely with…

Life science IPOs: listing in UK or US

The decision to take a company public is never taken lightly. For life science companies, however, that decision is further complicated by deciding where to list? Life science IPOs are back…

Turning the tide: attracting transatlantic biotech issuers to AIM

London Stock Exchange is a diversified international exchange Group that sits at the heart of the world’s financial community. Through its markets, the Group offers international business, and investors, unrivalled access to Europe’s…

The Californian biotech who brought a $100m IPO to UK shores

Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to…

View of an active private life science investor

In March, Jon Moulton increased his shareholding in Redx Pharma as the biotech company successfully completed it’s IPO on London’s AIM. Jon has long experience of turnarounds, having invested in…

From developing highly differentiated ‘best-in-class’ new drugs to IPO

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes…

Using conformational design to target a $9bn therapeutic market

C4X Discovery, a Manchester-based, AIM-listed Company which uses an NMR-based technique to optimise drug discovery, possess a unique drug discovery technology has the potential to cut preclinical development times and cost by…